(Albany, United States) As per DelveInsight’s assessment, globally, the Non-Muscle Invasive Bladder Cancer Pipeline constitutes 25+ key companies continuously working towards developing 30+ Non-Muscle Invasive Bladder Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Non-Muscle Invasive Bladder Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Non-Muscle Invasive Bladder Cancer NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Non-Muscle Invasive Bladder Cancer Pipeline treatment landscape of the report, click here @ Non-Muscle Invasive Bladder Cancer Pipeline Outlook

 

Key Takeaways from the Non-Muscle Invasive Bladder Cancer Pipeline Report

• DelveInsight’s Non-Muscle Invasive Bladder Cancer Pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline treatment therapies.
• The leading companies working in the Non-Muscle Invasive Bladder Cancer Market include Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, and others.
• Promising Non-Muscle Invasive Bladder Cancer Pipeline CG0070, Pembrolizumab Injection, TLD1433 infusion and photodynamic therapy (PDT) treatment, Durvalumab, cis-UCA solution, ADSTILADRIN, TARA-002, N803 plus Bacillus Calmette-Guerin (BCG), VB4-845 Injection, PF-06801591, and others.
• On August 2023, AstraZeneca announced a study of phase 3 clinical trials for Durvalumab and BCG. The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.
• On August 2023, Ferring Pharmaceuticals announced a study of phase 3 clinical trias for ADSTILADRIN. Previous multi-dose Phase I and Phase II clinical studies have demonstrated that ADSTILADRIN is a safe and effective treatment for BCG-refractory and recurrent NMIBC. This Phase III study is designed to expand those observations using a high dose of ADSTILADRIN in patients that are “BCG Unresponsive” which refers to patients with high-grade NMIBC who are unlikely to benefit from and should not receive further intravesical BCG.

 

Non-Muscle Invasive Bladder Cancer Overview

Non muscle-invasive bladder cancer (NMIBC) is a heterogeneous subclassification of urothelial carcinoma with significant variation in individual risk of recurrence and progression to muscle-invasive disease. It is a cancer found in the tissue that lines the inner surface of the bladder.

 

For further information, refer to the detailed Non-Muscle Invasive Bladder Cancer Unmet Needs, click here for Non-Muscle Invasive Bladder Cancer Ongoing Clinical Trial Analysis

 

Non-Muscle Invasive Bladder Cancer Emerging Drugs Profile

• APL-1202: Asieris Pharmaceuticals
• Pemigatinib: Incyte Corporation 
• VAX 014: Vaxiion Therapeutics

 

Non-Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. Phase III include, Asieris Pharmaceuticals.

 

Request a sample and discover the recent advances in Non-Muscle Invasive Bladder Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Non-Muscle Invasive Bladder Cancer Segmentation

 

Non-Muscle Invasive Bladder Cancer Drugs and Companies

• cis-UCA solution: BioCis Pharma Ltd
• ADSTILADRIN: Ferring Pharmaceuticals
• TARA-002: Protara Therapeutics

 

Non-Muscle Invasive Bladder Cancer Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Non-Muscle Invasive Bladder Cancer Therapeutics Market include-

Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, and others.

 

Dive deep into rich insights for drugs for Non-Muscle Invasive Bladder Cancer Pipeline, click here @ Non-Muscle Invasive Bladder Cancer Unmet Needs and Analyst Views

 

Scope of the Non-Muscle Invasive Bladder Cancer Pipeline Report

• Coverage- Global
• Companies- Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, and others.
• Therapies- CG0070, Pembrolizumab Injection, TLD1433 infusion and photodynamic therapy (PDT) treatment, Durvalumab, cis-UCA solution, ADSTILADRIN, TARA-002, N803 plus Bacillus Calmette-Guerin (BCG), VB4-845 Injection, PF-06801591, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Non-Muscle Invasive Bladder Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Non Muscle Invasive Bladder Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non Muscle Invasive Bladder Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. APL-1202: Asieris Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Pemigatinib: Incyte Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. VAX 014: Vaxiion Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Non Muscle Invasive Bladder Cancer Key Companies
21. Non Muscle Invasive Bladder Cancer Key Products
22. Non Muscle Invasive Bladder Cancer- Unmet Needs
23. Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
24. Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
25. Non Muscle Invasive Bladder Cancer Analyst Views
26. Non Muscle Invasive Bladder Cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services